Wednesday, 20 July 2011

Yangzijiang Shipbuilding - Cheapest Chinese shipbuilder (CIMB)

OUTPERFORM Maintained
S$1.33 Target: S$2.05
Mkt.Cap: S$5,085m/US$4,183m

Higher interest income and gains in 2Q11
Maintain OUTPERFORM. Despite a +30% yoy earnings guidance for 1H11, we believe qoq earnings could be 5-10% lower given fewer deliveries of high-margin vessels. Interest income and forex gains could also be key drivers for 2Q11, contributing about 40% of earnings. We commend YZJ for its ability to keep its gross margin high at about 24% from the execution of pre-crisis orders. YZJ’s current valuation of 6x CY12 P/E looks undemanding as it is 50% below its Chinese peers’ average of 12x and its own historical average of 11x since listing. Its US$6bn order book is also firm with low cancellation risk. Catalysts include firm contracts from Peter Döhle (US$800m) and the potential exercise of options by Seaspan for a series of 10,000 TEU containerships. We maintain our OUTPERFORM call and target price of S$2.05, still based on 14x CY12 core shipbuilding earnings.

The news
In response to a recent share price plunge and a news article about European exposure, YZJ announced that 1) it has no immediate plans for convertible bonds, 2) there has been increasing diversification in its order book with more Asian ship owners while existing long-term European customers have strong financial standing and payment track records, 3) it projects 30% yoy earnings growth in 1H11, and 4) management is considering share buybacks to protect minority interests.

Comments
+30% yoy for 1H11 but weaker; strong margin track record maintained. Despite the positive earnings guidance for 1H11 (results to be announced on 11 Aug), we believe qoq earnings could come in 5-10% lower at about Rmb870m from fewer deliveries of high-margin vessels. Recall that four of the 17 vessels delivered in 1Q11 were secured pre 2008 with higher gross margins. Management clarified that several high-margin projects were completed in beginning-Jul instead of Jun 2011, resulting in a lower number of vessels delivered qoq. However, we believe YZJ should continue to keep its gross margin high at about 22% in 2Q11 (1H11: 24%) on the back of efficient yard utilisation and a strong execution track record.

Non-shipbuilding income to climb. We expect interest income and gains from marked-to-market valuations to contribute about 40% of 2Q11 earnings (1Q11: 42% of net profit) on the back of higher investment in financial assets (above Rmb10bn) and gradual YTD appreciation of Rmb.

Order book intact. Although 60% of its order book (estimated at about US$6bn) is dominated by European customers, we see low risk of cancellation as 1) most of its containerships were clinched pre 2008 with at least 20% deposits received, backed by additional 20% bankers’ guarantees, which have survived the crisis, and 2) bulk orders were mostly clinched post crisis at low market prices.

Valuation and recommendation
Cheaper than peers. YZJ’s current valuation of 6x CY12 P/E is 50% below the Chinese peer average of 12x CY12 P/E and its own historical average of 11x since listing, which we deem as undemanding. We see catalysts from Peter Döhle’s firm contracts (US$800m) and the potential exercise of options by Seaspan for a series of 10,000 TEU containerships. We keep our target price of S$2.05, still based on 14x CY12 core shipbuilding earnings.

Biosensors International (KimEng)

Up-to-date in 60 seconds
Background: Biosensors develops, manufactures and markets medical devices for interventional cardiology and critical care procedures. BioMatrixTM, its flagship product, is the world’s first commercially available drug eluting stent (DES) with a biodegradable polymer.

Recent development: Biosensors recently proposed to acquire the remaining 50% stake in JW Medical Systems (JWMS), to turn it into a wholly-owned subsidiary. JWMS is one of the top three DES players in China and has its own Excel brand stent. This strategic acquisition would allow Biosensors to market its BioMatrixTM product through JWMS’s distribution network in China.

Key ratios…
Price-to-earnings: 26.4x
Price-to-NTA: 3.9x
Dividend per share / yield: $0.0 / 0%
Net cash/(debt) per share: S$0.205
Net cash as % of market cap: 16%

Share price S$1.28
Issued shares (m) 1,344.941
Market cap (S$m) 1,721.53
Free float (%) 66%
Recent fundraising activities Mar 11: Placement of 216m new shares to Atlantis and Ever Union @ $0.9283
Financial YE 31 Mar
Major shareholders Autumn Eagle (20%), Atlantis (8%), Ever Union (8%)
YTD change +13.27%
52-wk price range S$0.790-1.410

Our view:
Long road to acquire JWMS. The plan to acquire JWMS fully was hatched in 2007 after the initial 50% acquisition. However, regulatory approval could not be obtained from China authorities. The eventual approval came after Biosensors’ founder and chairman sold his entire 18% stake at 88.88 cents to Hony Capital, a Chinese private equity firm, followed by the entry of another two strategic investors with strong exposure in China, namely, Atlantis Investment and Ever Union Capital.

Tapping Japan and China markets. Biosensors has a licensing agreement with Terumo Corp of Japan, which allows the latter to market BioMatrixTM stents under the Nobori brand exclusively in Japan. After the JWMS acquisition, Biosensors would be ready to tap into another huge US$500m DES market in China. Approval for its BioMatrixTM stent is expected to come this year or next.

Developing a next-generation product. Even as it is marketing its BioMatrixTM product, Biosensors is already developing a next-generation DES product, BioFreedomTM, which is polymer-free, thereby reducing the risk of clotting.

Race to penetrate markets. In the absence of another commercially available competing product currently, Biosensors needs to race to penetrate markets. If this pans out well, it could see double-digit profit growth, which would then make it a worthy stock for investment. The stock currently trades at FY11 PER of 26.4x.

Keppel Tele & Tran - Record operating profits (CIMB)

S$1.37 Target: S$1.61
OUTPERFORM Maintained
Mkt.Cap: S$757m/US$623m

• In line; maintain OUTPERFORM with higher TP of S$1.61 (from S$1.57). 2Q11 core net profit (S$14.9m, +8.2% yoy) came largely in line with our expectations. 1H11 core net profit formed 42% of our FY11 estimate. Key variances came from i)a slightly lower-than-expected topline offset by lower-than-expected operating costs leading to higher-than-expected margins, and ii) higher-than-expected depreciation and interest expense. Therefore, we tweak our operating expense assumptions, leaving our FY11-13 EPS estimates largely unchanged. However, our SOP-based target price rises from S$1.57 to S$1.61, as we peg M1’s market cap to our target. KPTT achieved record operating profit this quarter, which reflects the success of its efforts to strengthen its core operations. KPTT remains an OUTPERFORM and rerating catalysts could come from accretive data centre acquisitions and faster-thanexpected penetration into China.

• Core operations starting to contribute. Core operating profit came in at a record S$5.6m (+141% yoy, +31% qoq) as KPTT’s data centre operations started to contribute meaningfully. We also saw margin expansion in this quarter. The operating margin was 20.0% (+11.0% pts yoy, +6.0% pts qoq).

• Associates contributions. Associates contributed S$15.4m before tax (-6% yoy), with 56% attributable to M1 (S$8.6m) and 44% (S$6.8m) attributable to KPTT’s logistics, data centre and telco-related associates.

• Gearing increased. KPTT’s 2Q11 net gearing rose slightly from 0.56x to 0.62x. We believe this was due to ongoing capex required for its warehouse expansion plans in Singapore and Nanhai, China.

• Data centre updates. From our recent discussions with management, we sensed that demand for data centre services remained robust not only in Singapore but also globally. We believe management is on the prowl for accretive data centre acquisitions or could develop a new data centre to increase capacity.

• Expansion in China. Galvanising its involvement in Tianjin Eco-city, KPTT has recently signed an MOU in Jilin, China, to explore opportunities to develop a Jilin Food zone. Management sees opportunities to export its FMCG supply chain expertise into logistically-constrained cities in China.